These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 3565907)

  • 1. Use of hexadimethrine bromide as a heparin-neutralizing agent in canine plasma.
    Green RA; LaFollette KA; Greig B
    Am J Vet Res; 1987 Mar; 48(3):496-8. PubMed ID: 3565907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated coagulation time in monitoring heparinized dogs.
    Green RA
    Am J Vet Res; 1980 Nov; 41(11):1793-7. PubMed ID: 7212408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Modification of the global coagulation tests for the dog. Significance for the monitoring of heparin therapy].
    Mischke R; Nolte I
    Tierarztl Prax; 1991 Oct; 19(5):561-6. PubMed ID: 1759273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog.
    Hellebrekers LJ; Slappendel RJ; van den Brom WE
    Am J Vet Res; 1985 Jul; 46(7):1460-2. PubMed ID: 4026027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated coagulation time test: a convenient monitor of heparinization for dogs used in cardiovascular research.
    Wilkerson RD; Conran PB; Greene SL
    Lab Anim Sci; 1984 Feb; 34(1):62-5. PubMed ID: 6716959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a new potent heparin. 1 communication: Determinations of anticoagulant activity of a high potency heparin preparation in vivo using dog as an experimental animal and in vitro using dog and human plasma.
    Bhargava AS; Heinick J; Schöbel C; Günzel P
    Arzneimittelforschung; 1980; 30(6):993-6. PubMed ID: 7191280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats.
    Greene CE; Meriwether E
    Am J Vet Res; 1982 Aug; 43(8):1473-7. PubMed ID: 7103231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of polybrene for heparin neutralization in protein C activity assay.
    Harsfalvi J; Pfliegler G; Udvardy M; Boda Z; Tornai I; Rak K
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):357-61. PubMed ID: 2133212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of reagent batch on activated partial thromboplastin time in canine plasma and use of the ratio system for standardization].
    Mischke R
    Berl Munch Tierarztl Wochenschr; 2002; 115(5-6):225-9. PubMed ID: 12058600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a new potent heparin. 6th communication: The comparison of the anticoagulant effect of the sodium and calcium salts of a new potent heparin after s.c. injection in beagle dogs.
    Bhargava AS; Schöbel C; Günzel P
    Arzneimittelforschung; 1981; 31(1):79-82. PubMed ID: 7194097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The assay of factor VIII: C in heparinized plasma: a polybrene neutralization method.
    Cumming AM; Wensley RT; Delamore IW
    Thromb Haemost; 1986 Feb; 55(1):58-60. PubMed ID: 3085265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A new test for monitoring heparin therapy].
    Camici M; Evangelisti L; Giordani R
    Minerva Med; 1998 Sep; 89(9):345-9. PubMed ID: 9856125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assay of Factor XII clotting activity in heparinized plasma.
    Lämmle B; Tran TH; Duckert F
    Am J Clin Pathol; 1983 Oct; 80(4):474-7. PubMed ID: 6624710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of the human protein C activator, Protac, on the activated partial thromboplastin clotting times of plasmas, with special reference to the dog.
    Johnstone IB; Martin CA
    Can J Vet Res; 2000 Apr; 64(2):117-22. PubMed ID: 10805251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is the activated partial thromboplastin time suitable for monitoring of thrombosis therapy with high-dose standard heparin?].
    Hürzeler C; von Felten A
    Schweiz Med Wochenschr; 1994 Apr; 124(17):712-9. PubMed ID: 8202668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monitoring heparin therapy by thrombin time and activated partial thromboplastin time--a comparison].
    Lang M; Fey MF; Furlan M; Beck EA
    Schweiz Med Wochenschr; 1986 Nov; 116(48):1681-4. PubMed ID: 3798064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new principle in heparin assaying based on partial neutralization of heparin with polybrene.
    Talstad I
    Thromb Res; 1980 May 1-15; 18(3-4):485-91. PubMed ID: 7414543
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs.
    Freitas CF; Morganti RP; Annichino-Bizzacchi JM; De Nucci G; Antunes E
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):10-4. PubMed ID: 17201729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.